However, its role in primary tumors of 258 breast cancer patients showed that around 44% of patients were HSD3B1 positive and knockdown of HSD3B1 inhibited both cell proliferation and cell migration irrespective of estrogen receptor action [40]. Here, HSD3B1 is linked to breast carcinoma.